10:00 AM EST, 01/15/2025 (MT Newswires) -- Tempus AI ( TEM ) said Wednesday its US Food and Drug Administration-approved next-generation sequencing test xT CDx for solid tumor profiling is now available nationwide.

Using a normal-matched approach, where a solid tumor and a normal patient sample are sequenced in parallel, xT CDx can more accurately detect cancer-driving somatic variants, the company said.

All orders for tumor + normal match tests, previously conducted through the company's xT assay, will transition to xT CDx without changing the current ordering workflow, it added.

The company's shares were up 8.9% in recent trading.

Price: 34.67, Change: +2.84, Percent Change: +8.91